Myositis‐specific anti‐155/140 autoantibodies target transcription intermediary factor 1 family proteins
Top Cited Papers
Open Access
- 10 October 2011
- journal article
- myositis
- Published by Wiley in Arthritis & Rheumatism
- Vol. 64 (2), 513-522
- https://doi.org/10.1002/art.33403
Abstract
Objective To identify the 140‐kd autoantigen recognized by anti‐155/140 autoantibodies that are associated with adult cancer‐associated dermatomyositis (DM) and juvenile DM and to determine the clinical relevance of anti‐155/140 antibodies in a large cohort. Methods Sera from 456 DM patients were assessed for the presence of anti‐155/140 antibodies by immunoprecipitation using K562 cell extracts as substrate. Using immunoprecipitation and Western blotting, we then examined whether anti‐155/140–positive sera recognized transcription intermediary factor 1α (TIF‐1α), TIF‐1β, and TIF‐1γ. The clinical associations of antigen reactivity were also evaluated. Results Anti‐155/140–positive sera reacted with 140‐kd TIF‐1α in addition to 155‐kd TIF‐1γ. Among sera from 456 DM patients, 52 were reactive with both TIF‐1α and TIF‐1γ, while another 25 were reactive with TIF‐1γ alone. Additionally, 7 were reactive with TIF‐1β. Malignancy was more frequently found in adult patients with both anti–TIF‐1α and anti–TIF‐1γ antibodies than in those with anti–TIF‐1γ antibodies alone (73% versus 50%; P < 0.05). In addition to juvenile DM patients and middle‐aged and older DM patients with high percentages of malignancy, 8 “young adult” DM patients without malignancy had these autoantibodies. Conclusion Anti‐155/140 antibodies target TIF‐1 family proteins, TIF‐1α and TIF‐1β, in addition to TIF‐1γ. Since TIF‐1 proteins have significant roles in oncogenesis, these antibodies may be produced during misdirected antitumor immunity.This publication has 37 references indexed in Scilit:
- Dermatomyositis and polymyositisAnnals of the New York Academy of Sciences, 2010
- Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expressionRheumatology, 2009
- Polymyositis and dermatomyositisThe Lancet, 2003
- Laboratory testing in the diagnosis and management of idiopathic inflammatory myopathiesRheumatic Disease Clinics of North America, 2002
- Incidence of Malignant Disease in Biopsy-Proven Inflammatory Myopathy: A Population-Based Cohort StudyAnnals of Internal Medicine, 2001
- Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based studyThe Lancet, 2001
- Risk of Cancer in Patients with Dermatomyositis or PolymyositisNew England Journal of Medicine, 1992
- A New Approach to the Classification of Idiopathic Inflammatory MyopathyMedicine, 1991
- Dermatomyositis and MalignancyAnnals of Internal Medicine, 1976
- DERMATOMYOSITIS AND MALIGNANCY: A REVIEW OF THE LITERATUREAnnals of Internal Medicine, 1959